PKP2-ACM Natural History Study
← catalyst calendarNCT06644742 · readout ≤ 1,595 d
Sponsored by Rocket Pharmaceuticals Inc. (industry) · RCKT — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
36estimated
Sites
3
Countries
Netherlands, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Mar 2026 | estimated | When the study began enrolling |
| Primary completion | Dec 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cardiomyopathies
- Heart Diseases
- Cardiovascular Diseases
- Genetic Diseases
Primary outcomes
what the primary-completion date above is the date OFHeart rhythm and rate monitoring measures
measured 36 months
Cardiac biomarkers
measured 36 months
Permalink · RCKT's whole pipeline · Catalyst calendar · Every registered study · What changed